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Abstract
Nanotechnology is one of the premiere technologies available today, having expanded both as field of scientific
study and in the public consciousness. Despite this growth, the drawbacks, limitations and potential safety
hazards associated with the incorporation of nanotechnology into existing industries are still being learned. The
noticeable point is that there is no enough data available yet to analyze global use of nanotechnology from a
meta-perspective. Three challenges can be defined in light of nanotoxicology. One, materials that might prove to
be significantly toxic must be identified. Two, a system for the categorization of NP materials must be codified and
made available to toxicologists. Third, a better understanding of nanoparticles biological interactions must be
obtained, in order to make the best use of the first two goals. For all three, it must be remembered that research
standards need to be developed for the gathering of data on the nanoscale, as that level is where the NPs and the
patient’s biosystems will be interacting.
As requiring toxicologists to become nanotechnology experts would not be feasible, to properly incorporate the
care of nanotoxicity into the existing medical framework, a range of experts across multiple fields of study must
work in close synchronization. The focus needs to be on mechanism-driven research to ensure a solid scientific
foundation for the assessment of NP and their role in healthcare.
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Nanotechnology is one of the premiere technologies
available today, having expanded both as field of scien-
tific study and in the public consciousness. Despite this
growth, the drawbacks, limitations and potential safety
hazards associated with the incorporation of nanotech-
nology into existing industries are still being learned.
The noticeable point is that there is no enough data
available yet to analyze global use of nanotechnology
from a meta-perspective.
The conventional definition of a nanoparticle (NP) is a
material or materials with two or three dimensions, be-
tween 1 and 100 nm and possessing strange properties
related to the size, shape or chemical composition of the
material. The term nanotechnology can be defined as
“the manipulation, measurement, precision, modeling,
or manufacture of sub-100 nanometer scale matter” [1].
Today, over 800 consumer products are estimated to in-
corporate nanoparticles [2,3].
Of particular interest to the medical field is the poten-
tial advantage of nanotechnology in both diagnostic and
therapeutic approaches. The ability to operate at the cel-
lular or intercellular level could lead to dramatic leaps in
the patient care. As of this writing, NPs are being devel-
oped to meet a variety of needs, however very few NPs
have made it out of the testing phase. Over the last five
years, production of NPs has increased five-fold. The
current approximation is that more than 580 companies
over 30 countries manage and produce some 1,317 NP-
based projects, from textiles to wound dressings [2].
Some scientists have speculated that nanotechnology is
growing because of recognition that a targeted, cell-by-
cell approach brings greater benefits than an undifferen-
tiated approach [4].
However, there are significant concerns associated
with the use of NPs. The primary concerns are with how
easily NPs can penetrate cell membranes. When com-
pared to non-NPs, NPs can more easily pass into various
biological structures, creating a potentially toxic effect.
On a macro-scale, the increasing presence of NPs on an
environmental level may also have negative conse-
quences, however, the current knowledge is not enough
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to reach a convincing consensus. For instance, NPs
designed to act as chemical catalysts for particular
chemical reactions, might, due to their physical structure
have undesirable effects in the human body. In one par-
ticular case, the respiratory system was harmed by NPs
[5-7]. With these concerns, a growing body of profes-
sionals is seeking development of toxicology screenings
that specifically target NPs [8,9].
Categorizations of NPs tend to fall into carbon-based
NPs, i.e. fullerenes and carbon nanotubes, and inorganic
NPs, ones based on the metal oxides (iron oxide, cerium
oxide, titanium dioxide, silicon dioxide), metals (gold
and silver), and semiconductor NPs or so-called
quantum dots [10]. All of the above could have haz-
ardous effects but a comprehensive analysis of each
NP class has yet to occur. NPs production can be
divided into four major steps such as gas-phase, vapor
deposition, colloidal and attrition, and each step could
cause toxicity by gastrointestinal, pulmonary or skin
exposure [11].
The danger that NPs pose is related to their very na-
ture. Due to their miniscule size, NPs can collect nearly
anywhere in a biological system. Whether a person
absorbs NPs in the process of taking nano-based drugs,
through topical skin applications or by inadvertent inhal-
ation of NPs makes no difference when considering the
potential harm due to nanotoxicity. The toxic effects
might be compounded in cases involving NPs deliber-
ately manufactured for use in industry as those NPs
might promote harmful chemical reactions once in
the body.
Specifically, the small scale of NPs allow them to by-
pass the usual barriers to cell uptake and can enter sen-
sitive tissues such as bone marrow, lymph nodes, spleen
and the heart by way of blood circulation or lymphatic
channels [12]. Of course, such entry depends on the
chemical makeup of the NPs. When endocytosis occurs
with a foreign matter such as NPs, there is a risk of in-
flammatory activity, sometimes pro-oxidant, sometimes
antioxidant [12,13]. There is evidence that the body pro-
duces an oxidative stress response, which, when coupled
with mitochondrial distribution may result in some dis-
advantages that remain to be clarified. NPs at the scale
of biological macromolecules could easily hybridize, as
several features of certain NPs give them advantaged
when compared to biological molecules. For instance,
NPs introduced to the body through sunscreen pass
through the skin due to their small size, avoid
neutralization by the immune system due to their com-
position, and their tendency to produce free radicals
have concerned experts who fear that if sunscreen NPs
prove toxic, they might be impossible to flush out of the
body [14]. Other dangers include protein degradation
brought on by the large surface area of NPs compared to
the small surface area of larger particles [15], which can
be observed in various processes with taking DNA
macromolecules and using them to solubilize highly
hydrophobic single-walled carbon nanotubes [16]. These
carbon nanotubes can induce DNA strand breaks due to
a greater amount of intrusion into the cell nuclei, or
even create micronuclei [17].
Dosing also becomes a greatly complicated affair on
the nanoscale, with the potential benefits being weighted
against the danger of exposing a compromised organism
to NPs [12]. There are many aspects of medicinal NPs
use that must be defined, such as the effects of the NP’s
size, shape and chemical composition. Furthermore,
questions exist as to how long a NP dose remains in the
body. Are they eventually flushed out of a particular cell?
If so, how long does that process take, from start to fin-
ish? When the body absorbs NPs for therapeutic pur-
poses, do they simple provide an enhanced version of
the effects seen in large particles or are the NPs creating
entirely new effects, with the added danger of unfore-
seen side effects [18,19]? And what of “antigenic chal-
lenges”? Could engineered NPs diminish the function of
the immunological apparatus? Can the effects of NPs be
predicted with any type of accuracy? Or precise mea-
surements taken at that scale? And in the case of ad-
verse effects, the small scale of NPs means NPs could
affect organs very distant from their point of entry. Even
the use of targeting ligands applied to the surface of NPs
to ensure delivery of a nanodevice to a specific anatom-
ical location or cell type. One case to focus on is the use
of flexible hydrophilic polymers, specifically those in-
corporating polyethylene glycol (PEG), which limit
opsonization of the NPs and give them opportunity to
remain in circulation for longer time periods [20]. Due
to the fact that the NPs remained circulating, they
reached various additional structures and, depending on
the type of NP, build up in those new structures. An ex-
ample comes from the early days of research of the bio-
distribution of model polystyrene NPs, which were
coated with poloxamers. These elements attach to par-
ticle surfaces via their hydrophobic areas, and the hydro-
philic sections come through into the aqueous medium
and these particles found to concentrate to significant
extent in the bone marrow, specifically the sinusoidal
bone marrow endothelium [21]. Other areas of accumu-
lation were the brain, gut, spleen, and lymph nodes
[22,23]. Obviously the potential dangers of having for-
eign NPs building up in the body cannot be ignored.
Thus the discipline of nanotoxicology, which seeks to
define and demarcate the effects caused by artificial NPs
and establish the relationship between NPs and toxicity.
Up until the present day, those studying the pheno-
menon of nanotoxicology focused on NPs made of con-
ventional material, TiO2, ZnO and Ag, for example, with
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the occasional special material such as carbon nano-
tubes. With the recent advances in nanotechnology how-
ever, that approach will no longer allow toxicologists to
stay on top of the development and potential hazards
posed by the increasingly sophisticated NPs now in pro-
duction, build using multicomponent materials, hybrid
materials that sit on the line between organic and inor-
ganic, and materials designed to change their behavior
based on either the environment or a received signal
[24]. As such complicated NPs became more and more
widely accepted, there has been a greater recognition of
the lack of toxicological knowledge about these new
substances [25].
Therefore, three challenges can be defined in light of
this new information. One, materials that might prove to
be significantly toxic must be identified. Two, a system
for the categorization of NP materials must be codified
and made available to toxicologists. Third, a better
understanding of NPs’ biological interactions must be
obtained, in order to make the best use of the first two
goals. For all three, it must be remembered that research
standards need to be developed for the gathering of data
on the nanoscale, as that level is where the NPs and the
patient’s biosystems will be interacting.
As requiring toxicologists to become nanotechnology
experts would not be feasible, to properly incorporate
the care of nanotoxicity into the existing medical frame-
work, a range of experts across multiple fields of study
must work in close synchronization. The focus needs to
be on mechanism-driven research to ensure a solid sci-
entific foundation for the assessment of NP and their
role in healthcare.
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